Precise DAPT vs TreatHF

The PRECISE-DAPT score calculator provides the percentage probability of major bleeding at twelve months in patients with coronary artery disease treated with dual antiplatelet therapy after coronary stenting. This tool is designed to support clinicians decision making for dual antiplatelet therapy duration after coronary stenting. This calculator specifically designed for mobile devices, provides a rapid and intuitive assessment of patients' bleeding risk. Additional features include: – PRECISE-DAPT score calculation – Estimate of bleeding risk at 12-months for TIMI major and TIMI major or minor bleeding – Bleeding risk status according to the original score categories – Reporting system including all relevant information regarding the antiplatelet therapy selection and stenting procedure – An advanced e-mail reporting system to share information with the patient or other clinicians The PRECISE-DAPT score calculator includes 5 predictive risk factors to calculate the probability of major bleeding: Age Creatinin Clearance Haemoglobin levels White blood cell count History of previous spontaneous bleeding The score has been developed from a collaborative dataset including 14,963 patients from 8 randomized clinical trials, enrolled in more than 130 clinical sites and 12 countries worldwide. The PRECISE-DAPT Risk Score has been externally validated in two independent datasets. The PRECISE-DAPT Score and all related materials are for exclusive use of health care professionals and is intended as a supportive risk assessment tool which should never replace clinical judgment, physician–patient relationship or medical advice. Treatment risks and benefits should always be considered in the context of a comprehensive professional clinical assessment, taking into account all available data and treatment options. Physicians and other healthcare providers should always exercise their own clinical judgment for any given situation.

TreatHF is a clinical decision support app that provides clinicians individualized therapy suggestions for their symptomatic heart failure patients and provides guidance on the use of each therapy. • Enter patient indications • Review individualized next steps for medical therapy • Email or print a summary of the next steps • Reference detailed information for - Initiation, titration, and monitoring of each medication - Guidance for optimizing your overall medication strategy. Content in this app is derived from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction, and the 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. The information and recommendations in this clinical decision support app are not meant to represent the only or best course of care nor replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.